Click Therapeutics, a New York-based provider of digital therapeutics, secured $50 million in Series D funding from Boehringer Ingelheim. The raise comes with a strategic partnership wherein Click Therapeutics will take on full product responsibility for Boehringer Ingelheim’s investigational treatment for schizophrenia and support its commercialization.
CT-155, the companies’ co-developed digital therapeutic, is designed to work in conjunction with standard antipsychotic therapy. The solution, intended for adult schizophrenia patients experiencing negative symptoms, relies on interactive psychosocial intervention techniques.
“Boehringer Ingelheim’s selection of Click to deliver CT-155 to patients is powerful validation of our vision and the capabilities we have spent over a decade building,” David Benshoof Klein, Click Therapeutics’ CEO and founder, said in a statement. “We are eager to take the lead with CT-155 and are focused on getting this FDA-designated Breakthrough Device to patients after clearance by the FDA.”
